<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BioWorld Asia</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>South Korea streamlines biosimilar review, clinical trials</title>
      <description>
        <![CDATA[South Korea is rolling out regulatory changes to speed biosimilar development, including reforms to shorten review timelines, ease phase III trial requirements and simplify oversight of manufacturing changes.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/730137</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730137-south-korea-streamlines-biosimilar-review-clinical-trials</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-vials.webp?t=1588350331" type="image/png" medium="image" fileSize="310068">
        <media:title type="plain">Drug vials and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Amplia halts enrollment in phase II pancreatic cancer trial </title>
      <description>
        <![CDATA[Amplia Therapeutics Ltd. has halted recruitment in its phase II Amplicity trial in advanced pancreatic cancer due to three dose-limiting toxicities related to the chemotherapy regimen, modified FOLFIRINOX (mFOLFIRINOX), which is being administered in combination with lead compound narmafotinib (AMP-945), a focal adhesion kinase inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730134</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730134-amplia-halts-enrollment-in-phase-ii-pancreatic-cancer-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/pancreatic-cancer-pancreas-3D.webp?t=1729610305" type="image/jpeg" medium="image" fileSize="283423">
        <media:title type="plain">Illustration of cancer in the pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Best of BioWorld: Q1</title>
      <description>
        <![CDATA[A selection of top news from January through March 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730121</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730121-best-of-bioworld-q1</link>
    </item>
    <item>
      <title>Sector tariff now more than a threat – for some Rx companies</title>
      <description>
        <![CDATA[After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump finally delivered it. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730236</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730236-sector-tariff-now-more-than-a-threat-for-some-rx-companies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tariff-trade-illustration.webp?t=1746219221" type="image/jpeg" medium="image" fileSize="370006">
        <media:title type="plain">Digital globe illustrating pharma trade, tariffs</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma financings nearly double vs. 2025 to $25.1B</title>
      <description>
        <![CDATA[Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in the Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730235</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730235-biopharma-financings-nearly-double-vs-2025-to-251b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gray-and-green-glass-dollar-symbols-with-arrow-pointing-up.webp?t=1731016850" type="image/jpeg" medium="image" fileSize="116588">
        <media:title type="plain">Gray and green glass dollar symbols with arrow pointing up</media:title>
      </media:content>
    </item>
    <item>
      <title>Hematopoietic stem cell research points to leukemia’s early roots</title>
      <description>
        <![CDATA[Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730205</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730205-hematopoietic-stem-cell-research-points-to-leukemias-early-roots</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells.webp?t=1588880225" type="image/png" medium="image" fileSize="554020">
        <media:title type="plain">Cancer and blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Five-drug VIPOR regimen shows promise in aggressive blood cancer </title>
      <description>
        <![CDATA[Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730204</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730204-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/ICKSH_ViPOR-scans-4-1.webp?t=1775073716" type="image/jpeg" medium="image" fileSize="427849">
        <media:title type="plain">PET scans showing before and after treatment with VIPOR</media:title>
        <media:description type="plain">Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute</media:description>
      </media:content>
    </item>
    <item>
      <title>Regulatory actions for April 7, 2026</title>
      <description>
        <![CDATA[Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: 4DMedical, Abbisko, Eisai, GSK, Merck, SS Innovations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730114</guid>
      <pubDate>Tue, 07 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730114-regulatory-actions-for-april-7-2026</link>
    </item>
    <item>
      <title>Other news to note for April 7, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Adagene, Amgen, AP Biosciences, Aurinia, Axsome, Biocytogen, Daiichi Sankyo, Enodia, Everest Medicines, Frontier Medicines, Incyte, Kezar, LG Chem, Lupin, Nuvation, Shionogi, Taisho, Takeda, Tanabe, Tasly, Visufarma, Zai Lab.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730113</guid>
      <pubDate>Tue, 07 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730113-other-news-to-note-for-april-7-2026</link>
    </item>
    <item>
      <title>In the clinic for April 7, 2026</title>
      <description>
        <![CDATA[Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Adagene, Braveheart, Connect, Gan & Lee, Hengrui, Simcere, Takeda.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730112</guid>
      <pubDate>Tue, 07 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730112-in-the-clinic-for-april-7-2026</link>
    </item>
    <item>
      <title>Financings for April 7, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: 4DMedical, Adagene, Hangzhou Diagens, Stairmed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730111</guid>
      <pubDate>Tue, 07 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730111-financings-for-april-7-2026</link>
    </item>
    <item>
      <title>Appointments and advancements for April 7, 2026</title>
      <description>
        <![CDATA[New hires and promotions in the biopharma and med-tech industries in Asia-Pacific, including: Telix, Transcenta.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730110</guid>
      <pubDate>Tue, 07 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730110-appointments-and-advancements-for-april-7-2026</link>
    </item>
    <item>
      <title>News in brief</title>
      <description>
        <![CDATA[BioWorld Asia briefs for April 7, 2026]]>
      </description>
      <guid>http://www.bioworld.com/articles/435994</guid>
      <pubDate>Tue, 07 Apr 2026 01:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435994-news-in-brief</link>
    </item>
    <item>
      <title>Lilly taps Insilico AI in $2.75B deal to expand pipeline options</title>
      <description>
        <![CDATA[Eli Lilly and Co. is deepening its investment in artificial intelligence-driven drug discovery through a multibillion-dollar expansion of its collaboration with Hong-Kong listed Insilico Medicine Inc. in a move that could broaden its reach into next-generation metabolic therapies. Under the deal terms, Insilico is eligible to receive $115 million up front, plus development, regulatory, and commercial milestone payments worth $2.75 billion, in addition to sales-based royalties. In exchange, Lilly gains exclusive global rights to develop and commercialize multiple candidates generated using Insilico’s AI platform, including preclinical oral therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730091</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730091-lilly-taps-insilico-ai-in-275b-deal-to-expand-pipeline-options</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Pill-in-immersive-interface.webp?t=1621455412" type="image/png" medium="image" fileSize="279752">
        <media:title type="plain">Pill in immersive interface</media:title>
      </media:content>
    </item>
    <item>
      <title>Otsuka to acquire PTSD drugmaker Transcend in $1.2B deal </title>
      <description>
        <![CDATA[Otsuka Pharmaceutical Co. Ltd. is taking a neuroplastogen approach to posttraumatic stress disorder (PTSD) through its planned $1.22 billion acquisition of Transcend Therapeutics Inc. The deal gives Tokyo-headquartered Otsuka access to Transcend’s lead asset, TSND-201, an oral neuroplastogen that has begun patient recruitment for a phase III study in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730090</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730090-otsuka-to-acquire-ptsd-drugmaker-transcend-in-12b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Brain-with-handshake-and-cityscape.webp?t=1609792702" type="image/png" medium="image" fileSize="549630">
        <media:title type="plain">Brain with handshake and cityscape</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730089</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>China-developed triple incretin enters global diabetes race</title>
      <description>
        <![CDATA[A next-generation triple incretin therapy jointly developed by Novo Nordisk A/S and China’s United Biotechnology outperformed semaglutide in a phase II trial, signaling intensifying competition in the GLP-1 obesity and diabetes market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730088</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730088-china-developed-triple-incretin-enters-global-diabetes-race</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-Metabolic-glucose-bloodstream.webp?t=1674056639" type="image/png" medium="image" fileSize="1313266">
        <media:title type="plain">Illustration of glucose molecules in a bloodstream</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea roundup: Alteogen, Celltrion lead biotech deals</title>
      <description>
        <![CDATA[Subcutaneous formulation technology, microbiomes and oncological assets drove dealmaking in South Korea’s biotech sector this week.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/730087</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730087-korea-roundup-alteogen-celltrion-lead-biotech-deals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Celltrion-Kobiolabs-3-26.webp?t=1774632497" type="image/jpeg" medium="image" fileSize="738862">
        <media:title type="plain">Seo Jin-seok of Celltrion (right) with Ko Kwang-pyo of Kobiolabs (left)</media:title>
        <media:description type="plain">Seo Jin-seok, CEO, Celltrion (right) with Ko Kwang-pyo, founder and CEO, Kobiolabs (left).</media:description>
      </media:content>
    </item>
    <item>
      <title>Simcere’s rademikibart meets phase III endpoints in atopic dermatitis </title>
      <description>
        <![CDATA[Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729969</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/monoclonal-antibody-mab.webp?t=1713364043" type="image/jpeg" medium="image" fileSize="243312">
        <media:title type="plain">Monoclonal antibody illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Braveheart finds phase II positive for cardiac myosin inhibitor </title>
      <description>
        <![CDATA[Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology’s Annual Scientific Session and Expo in New Orleans showed BHB-1893 treatment was associated with rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint of the study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729968</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729968-braveheart-finds-phase-ii-positive-for-cardiac-myosin-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cross-section-valves.webp?t=1626905884" type="image/png" medium="image" fileSize="922624">
        <media:title type="plain">3D illustration of heart cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>Regulatory actions for March 31, 2026</title>
      <description>
        <![CDATA[Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Deciphera, Eisai, GC, GSK, Immunitybio, Mars Bioimaging, Nuvation, Ono, OS Therapies, Pharming, Regeneron, Sanofi, Tarsus, Viatris.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729994</guid>
      <pubDate>Tue, 31 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729994-regulatory-actions-for-march-31-2026</link>
    </item>
    <item>
      <title>Other news to note for March 31, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: 20/20 Biolabs, Apnimed, Aska, Belief, Biocytogen, Biogen, Bio-Thera Solutions, Corxel, Eisai, Everest Medicines, Glyconex, Grand Life, Insilico Medicine, Intas, Inscobee, Lakeshore, Mindwave Innovations, Moonlight, Nippon Kayaku, Novartis, Oceanpine Merger Sub, Oceanpine Skyline, Oscotec, Rokit Healthcare, Shionogi, Yatiri.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729993</guid>
      <pubDate>Tue, 31 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729993-other-news-to-note-for-march-31-2026</link>
    </item>
    <item>
      <title>In the clinic for March 31, 2026</title>
      <description>
        <![CDATA[Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Brightgene, Dizal, Harbour, Immunexpress, Innovent, Novo Nordisk, Otsuka, Prestige, Radiopharm, United Laboratories.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729992</guid>
      <pubDate>Tue, 31 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729992-in-the-clinic-for-march-31-2026</link>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729898</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729898-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Imbiologics crosses $1B market cap with Kosdaq debut </title>
      <description>
        <![CDATA[Imbiologics Corp.’s market capitalization reached ₩1.5 trillion (US$1.02 billion) on its Kosdaq debut March 20, as the biotech seeks to become a leading antibody drugmaker for autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729897</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729897-imbiologics-crosses-1b-market-cap-with-kosdaq-debut</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ha-Gyong-sik-CEO-Imbiologics-3-20.webp?t=1774038809" type="image/jpeg" medium="image" fileSize="550552">
        <media:title type="plain">Ha-Gyong-sik, CEO, Imbiologics</media:title>
        <media:description type="plain">Imbiologics CEO Ha-Gyong-sik at the company's IPO ceremony.</media:description>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729896</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729896-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere’s PD-L1/IL-15 bispecific sees early edge in bladder cancer </title>
      <description>
        <![CDATA[Early clinical data from Simcere Pharmaceutical Group Ltd. suggest its PD-L1/IL-15 bispecific antibody, SIM-0237, could emerge as a next-generation contender in Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729895</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729895-simceres-pd-l1-il-15-bispecific-sees-early-edge-in-bladder-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Bladder-cancer.webp?t=1588879220" type="image/png" medium="image" fileSize="372235">
        <media:title type="plain">Bladder cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Australia’s R&amp;D reset puts biotech translation in focus </title>
      <description>
        <![CDATA[Australia is attempting a once-in-a-generation reset of its innovation system, and biotech industry leaders have lauded the federal government’s independent review into Australia's slipping R&D ranks and its proposals to reverse the decline.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729894</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729894-australias-r-and-d-reset-puts-biotech-translation-in-focus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Light-bulbs.webp?t=1675461439" type="image/png" medium="image" fileSize="190883">
        <media:title type="plain">Light bulb shines next to extinguished ones</media:title>
      </media:content>
    </item>
    <item>
      <title>Kintor’s KX-826 meets phase III endpoints in alopecia  </title>
      <description>
        <![CDATA[Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729893</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729893-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Alopecia.webp?t=1773953185" type="image/jpeg" medium="image" fileSize="1021257">
        <media:title type="plain">Alopecia - hair loss </media:title>
      </media:content>
    </item>
    <item>
      <title>China’s pharma rise rattles US policymakers </title>
      <description>
        <![CDATA[U.S. lawmakers and industry experts are raising alarm over China’s expanding dominance across the pharmaceutical supply chain, warning that reliance on Chinese inputs poses a growing national security and public health risk.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729830</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729830-chinas-pharma-rise-rattles-us-policymakers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-and-US-flags.webp?t=1623269249" type="image/png" medium="image" fileSize="378844">
        <media:title type="plain">China and U.S. flags</media:title>
      </media:content>
    </item>
  </channel>
</rss>
